Challenges in Inflammatory Bowel Disease, 2nd Edition
July 2006, Wiley-Blackwell
Turn to Challenges in Inflammatory Bowel Disease (IBD) when you need an expert opinion on the new, unusual or controversial areas of IBD and not just the tried and tested information. Current and concise reviews of the latest scientific discoveries are translated into cutting-edge clinical guidance to address those challenging cases faced by every medical team caring for patients with IBD.
Refer to this book to answer burning questions, to read an in depth review of the controversial topics and to provide a clear explanation of issues.
1 Global changes in incidence.
2 The role of genetics in inflammatory bowel disease.
3 Microbial sensing in the intestine by pattern recognition receptors.
4 The role of bacteria.
5 The appendix - how might it influence susceptibility to ulcerative.
colitis: the legend of Qebehsenuef.
II Diagnosis and assessment.
6 What are the controversies in histopathological diagnosis?.
7 The challenges of using capsule endoscopy in the diagnosis and management of inflammatory bowel disease.
8 Cross-sectional imaging of inflammatory bowel disease.
III Management of ulcerative colitis.
9 Mesalazine for maintenance therapy in ulcerative colitis - how much, how long?.
10 Refractory distal colitis.
11 Pharmabiotics and inflammatory bowel disease - on the verge of evidence-based medicine.
12 Current controversies in the surgical management of ulcerative colitis.
13 What are the causes and treatment of ileoanal pouch dysfunction?.
IV Management of Crohn's disease.
14 Is mesalazine useful in Crohn's disease?.
15 Steroids or nutrition?.
16 Do antibiotics have a role in Crohn's disease?.
17 The optimal use of infliximab in Crohn's disease.
18 Designer drugs: from bench to bedside.
19Current controversies in the surgical management of Crohn's disease.
20 Perianal Crohn's disease.
21 What is dysplasia?.
22 Colonoscopic surveillance - if and when?.
23Cancer: new colonoscopic techniques.
24 Molecular markers - a realistic hope?.
25 Adenomas versus dysplasia associated lesion or mass - recognition and management?.
V Special management problems.
26 Growth impairment in children.
29 Can prognosis of ulcerative colitis be predicted?.
Professor Neil J. Mortensen, John Radcliffe Hospital, Oxford, UK
Professor A. Hillary Steinhart, Mount Sinai Hospital, Toronto, Canada
Professor John H. Pemberton, Mayo Clinic, Rochester, US
Dr Bryan F. Warren, John Radcliffe Hospital, Oxford, UK
- Focuses on current issues which are relevant to management of the disease
- Each chapter gives a balanced overview of the topics written by experts in the field
- Covers all aspects from investigation into the scientific basis of the disease through to its management and prognosis
"This book will appeal to all those with an interest in IBD and a desire to explore the latest evidence driving both scientific research and clinical practice. Its strength is that it is limited to areas of controversy and change, and as such will undoubtedly run to many more editions."
"This book is a worthy edition to anyone's library who has a particular interest in the field. It is extensively referenced, well illustrated and represents excellent value for money."
From a review of the first edition:
"The editors and publishers have succeeded admirably in at least three respects... Firstly, they have assembled an all-star cast of contributors ... Secondly, they have constructed this monograph ingeniously. Each chapter title is phrased as a question, which is then examined critically with scores of references that are pertinent and up to date. As a third defining feature of this ambitious volume, the editors have demanded and received from their authors highly critical analyses of "the most recently available evidence". The authors analyse and interpret the evidence in ways that allow each chapter to reach reasonably well founded conclusions."